Drugs / Pan-T booster co-expressing MSLN CAR T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05693844 | Jan 2023 → Dec 2025 overdue | — | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pan-T booster co-expressing MSLN CAR T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05693844 ↗ |
| Modality | Cell therapy | “novel CAR T cell system targeting mesothelin (MSLN) antigen” NCT05693844 ↗ |
| Target | MSLN | “targeting mesothelin (MSLN) antigen” NCT05693844 ↗ |